We studied the effects of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), administered for 24 weeks to a group of ten patients with primary hypercholesterolemia, in order to evaluate the drug's efficacy in improving the apolipoprotein profile. The patients received simvastatin once daily in dosages varying from 10 to 40 mg. Significant reductions were observed in total cholesterol (30%), low-density lipoprotein cholesterol (40%), total cholesterol/high-density lipoprotein cholesterol (47%), and apolipoprotein B (19%), and a significant increase in high-density lipoprotein (24%) and apolipoproteins AI (17%) and AII (25%). In only one patient was it necessary to also use cholestyramine to help correct the lipid levels. We may thus conclude that simvastatin, in a single daily dose, has a favorable effect on the lipid, lipoprotein, and apoliprotein profiles in a large proportion of patients with primary hypercholesterolemia.

Simvastatin and the apolipoprotein profile in primary hypercholesterolemia / M. Catalano, A. Aronica, G. Carzaniga, R. Seregni, T. Porro, M. Di Mauro, A. Libretti. - In: CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL. - ISSN 0011-393X. - 48:1(1990 Jul), pp. 85-90.

Simvastatin and the apolipoprotein profile in primary hypercholesterolemia

M. Catalano
Conceptualization
;
A. Aronica;G. Carzaniga
Membro del Collaboration Group
;
A. Libretti
Supervision
1990

Abstract

We studied the effects of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), administered for 24 weeks to a group of ten patients with primary hypercholesterolemia, in order to evaluate the drug's efficacy in improving the apolipoprotein profile. The patients received simvastatin once daily in dosages varying from 10 to 40 mg. Significant reductions were observed in total cholesterol (30%), low-density lipoprotein cholesterol (40%), total cholesterol/high-density lipoprotein cholesterol (47%), and apolipoprotein B (19%), and a significant increase in high-density lipoprotein (24%) and apolipoproteins AI (17%) and AII (25%). In only one patient was it necessary to also use cholestyramine to help correct the lipid levels. We may thus conclude that simvastatin, in a single daily dose, has a favorable effect on the lipid, lipoprotein, and apoliprotein profiles in a large proportion of patients with primary hypercholesterolemia.
Settore MED/09 - Medicina Interna
Article (author)
File in questo prodotto:
File Dimensione Formato  
Simvastatin and the apolipoprotein profile in primay hyperchole.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 5.23 MB
Formato Adobe PDF
5.23 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/581647
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact